# Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS

> **NCT00505401** · PHASE1 · COMPLETED · sponsor: **Istituto Superiore di Sanità** · enrollment: 27 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** recombinant HIV-1 Tat protein

## Key facts

- **NCT ID:** NCT00505401
- **Lead sponsor:** Istituto Superiore di Sanità
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2011-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505401, "Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00505401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*